A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

Bacteremia Clinical Trial

Official title:

A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects With Staphylococcus Aureus Bacteremia Including Infective Endocarditis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02208063
• Other study ID #: 0112
• Status: Terminated
• Phase: Phase 3
• Start date: December 2014
• Est. completion date: April 12, 2018

Study information

• Verified date: February 2020
• Source: Cumberland Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, randomized, open-label, noninferiority trial of telavancin versus standard IV therapy control (e.g., vancomycin, daptomycin, anti-staphylococcal penicillin (PCN), or cefazolin) in the treatment of subjects with complicated Staphylococcus aureus (S. aureus) bacteremia and SA right-sided infective endocarditis (SA-RIE).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 121
• Est. completion date: April 12, 2018
• Est. primary completion date: April 12, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years of age or older with at least one blood culture positive for S. aureus within 48 hours before randomization

• At least one of the following signs or symptoms of bacteremia:

• Temperature = 38.0°C

• White blood cell (WBC) count > 10,000 or < 4,000 cells/µL or > 10% immature neutrophils (bands)

• Tachycardia (heart rate > 90 bpm)

• Tachypnea (respiratory rate > 20 breaths/min)

• Hypotension (systolic blood pressure < 90 mmHg)

• Signs or symptoms of localized catheter-related infection

• At enrollment, subjects must have either 1) known right-sided infective endocarditis by Modified Duke's criteria 2) known complicated bacteremia, demonstrated as signs or symptoms of metastatic foci of S. aureus infection or 3) at least one risk factor for complicated bacteremia.

Exclusion Criteria:

• Treatment with any potentially effective (anti-staphylococcal) systemic antibiotic for more than 60 hours within 7 days before randomization. EXCEPTION: Documented resistance to the prior systemic antibacterial therapy

• Presence of an infection source that will not be managed or controlled within the first 3 days of study drug treatment

• Presence of prosthetic cardiac valve or cardiac device (eg, implantable cardioverter defibrillator [ICD]), permanent pacemaker, or cardiac valve support ring)

• Known or suspected left-sided infective endocarditis (LIE), by Modified Duke Criteria. NOTE: Right-sided infective endocarditis (RIE) is permitted

• Known or suspected osteomyelitis or meningitis. NOTE: Evidence of metastatic complications related to the primary infection such as right-sided endocarditis, septic arthritis, septic pulmonary emboli are permitted. S. aureus pneumonia is permitted

• Confirmed evidence (identification or gram stain) of a mixed polymicrobial infection with a Gram-negative pathogen that requires non-study antibiotic treatment with agent(s) that have activity against Gram-negative pathogens

Related Conditions & MeSH terms

• Bacteremia

Intervention

Drug:
• Telavancin

• Vancomycin

• Daptomycin

• Synthetic penicillin

• Cefazolin

Locations

Country	Name	City	State
United States	Remington-Davis Clinical Research	Columbus	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Cumberland Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With a Clinical Outcome of Cure at Test of Cure (TOC)	The efficacy endpoint of clinical outcome of cure at the test of cure (TOC) was determined by subjects who meet all of the following criteria, as determined by the investigator and adjudicated by the blinded independent efficacy adjudication committee (IEAC).; Alive at TOC; Resolution of all clinical signed and symptoms of the Staphylococcus aureus (S. aureus) infection at TOC; No evidence of microbiological persistence of relapse; No new foci of metastatic S. aureus infection after Day 8	Up to 8 weeks
Secondary	Number of Participants With an Investigator Clinical Outcome of Cure at TOC in the Microbiological All-treated (mAT) Population	The efficacy endpoint of Investigator clinical outcome of cure at the test of cure (TOC) was determined by the following criteria: Subject alive at TOC; Resolution of all clinical signs and symptoms of the S. aureus infection at TOC (unless explained by a more likely alternative diagnosis); No evidence of microbiological persistence or relapse; No new foci of metastatic S. aureus infection after Day 8	Up to 8 weeks
Secondary	Investigator Clinical Response (Success or Failure) at EOT in the Microbiological All-treated (mAT) Population	This efficacy endpoint was determined to be a clinical failure if the subject switched study antibiotic due to lack of clinical response	Up to 8 weeks
Secondary	Number of Participants With the Development of a New Metastatic Foci of S. Aureus Infection at Test of Cure (TOC) in the Microbiological All-treated (mAT) Populations	After Day 8, any sign or symptom leading to a subsequent confirmed diagnosis of a new metastatic foci of S. aureus infection	Day 8